| abstract |
The present disclosure generally relates to the field of evaluating a status, in particular, an age of an immune system based on a level of biomarkers, the biomarkers indicative of CD4 T cell phenotype, specifically for identifying levels of CD4 cytotoxic cells and/or activated regulatory (a Treg) CD4 T cells and thereby identify diseases and disorders, such as, systemic inflammation. |